SCHEMBL2434527

SCHEMBL2434527

COC(=O)Cc1ccc2nc(Nc3ccccc3Cl)oc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.55
RAB9A P51151 4/20 0.55
USP2 O75604 1/20 0.50
MAPT P10636 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
RAF1 P04049 1/20 0.48
BRAF P15056 1/20 0.48
GALK1 P51570 2/20 0.47
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
TYK2 P29597 1/20 0.47
JAK3 P52333 1/20 0.47
C1R P00736 4/20 0.46
ALDH1A1 P00352 2/20 0.46
ITGA4 P13612 5/20 0.44
ITGB1 P05556 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2435619 0.88 ITGA4 (0.53) NPC1RAB9AUSP2MAPTTDP1
SCHEMBL2436176 0.88 NPC1 (0.59) NPC1RAB9ASMN1; SMN2RAF1BRAF
SCHEMBL14591717 0.86 NPC1 (0.54) NPC1RAB9AMAPTSMN1; SMN2POLB
SCHEMBL27596597 0.85 MAPT (0.46) NPC1RAB9AUSP2MAPTTDP1
SCHEMBL2438782 0.84 NPC1 (0.51) NPC1RAB9AUSP2MAPTTDP1
SCHEMBL14500958 0.81 NPC1 (0.61) NPC1RAB9ASMN1; SMN2TP53RAF1
SCHEMBL27596620 0.80 NPC1 (0.54) NPC1RAB9AUSP2MAPTTDP1
SCHEMBL2434873 0.79 NPC1 (0.58) NPC1RAB9AUSP2MAPTTDP1
SCHEMBL14592200 0.79 ITGA4 (0.55) USP2MAPTTDP1ITGA4ITGB1
SCHEMBL2432871 0.78 NPC1 (0.51) NPC1RAB9AUSP2MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1346982-B1 VLA-4 INHIBITORS DAIICHI SEIYAKU CO (JP) 2011-09-14 EP disclosed
CN-100471838-C VLA-4 inhibitors DAIICHI SEIYAKU CO (JP) 2009-03-25 CN disclosed
CN-100396680-C Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2008-06-25 CN disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
US-7157487-B2 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-01-02 US disclosed
CN-1699363-A Vla-4 inhibitors DAICHI PHARMACEUTICAL CO LTD (JP) 2005-11-23 CN disclosed
US-20040110945-A1 Vla-4 inhibitors DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-10 US disclosed
CN-1483024-A Vla-4 inhibitors ��һ��������ҩ��ʽ���� 2004-03-17 CN disclosed
EP-1346982-A1 VLA-4 INHIBITORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110945-A1 Vla-4 inhibitors VCAM1, ITGA1, ITGB4 NPC1 1278/4885RAB9A 2530/4885USP2 4531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.